Naratriptan Biogaran (Naratriptan Hydrochloride)

Naratriptan is a triptan medication that acts on the migraine pathway to provide rapid relief of headache symptoms.

• Migraine attack: aborts headache pain and associated symptoms when taken at the onset of an attack.
• Migraine with aura: relieves pain and visual disturbances during an attack.
• Episodic migraine: reduces the severity and duration of acute migraine episodes.

• Naratriptan binds selectively to 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings. Activation of these receptors causes vasoconstriction of intracranial arteries and inhibits the release of pro‑inflammatory neuropeptides, thereby terminating the migraine cascade and alleviating headache pain.

Naratriptan may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Nausea: mild stomach upset or urge to vomit.
• Fatigue: feeling unusually tired.
• Tingling: paresthesia in extremities.
• Dry mouth: reduced salivation.
• Flushing: warm sensation with reddening of skin.

Serious or Rare Side Effects

• Chest discomfort: may mimic cardiac pain.
• Severe hypertension: abrupt rise in blood pressure.
• Serotonin syndrome: rare but potentially life‑threatening condition.
• Allergic reaction: rash, itching, swelling, or difficulty breathing.
• Cardiac arrhythmia: irregular heart rhythm.
• Ischemic stroke: very rare cerebrovascular event.

Before using Naratriptan, consider the following safety measures.

• Cardiovascular assessment: avoid if you have uncontrolled hypertension, coronary artery disease, or recent myocardial infarction.
• Medication history: inform your prescriber about other triptans or ergot derivatives you are taking.
• Age limitation: not recommended for children or adolescents under 18 years.
• Pregnancy and lactation: discuss risks with a healthcare professional before use.
• Drug interactions: review concomitant medications for potential interactions.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Naratriptan can interact with several drug classes; monitoring is essential.

Major Interactions (Avoid)

• MAO‑inhibitors: risk of serotonin syndrome.
• SSRIs/SNRIs: increased serotonin activity may precipitate serious reactions.
• Other triptans or ergot alkaloids: additive vasoconstrictive effects.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may enhance antihypertensive effect.
• CYP1A2 inhibitors (e.g., fluvoxamine): may raise naratriptan plasma levels.
• CYP3A4 inducers (e.g., carbamazepine): may reduce efficacy.
• Antihypertensives: monitor blood pressure for additive effects.